D
espite abundant evidence suggesting the critical involvement of inflammation in the pathogenesis of cardiac remodeling, 1, 2 targeting inflammatory cells in patients who have heart failure poses major challenges. Most inflammatory cell types exert a wide range of actions that may have context-dependent protective or detrimental functional consequences in the failing heart. Moreover, immune cells do not function as stable unidimensional effectors of a specific response, but exhibit remarkable plasticity and may undergo dramatic changes in the highly dynamic microenvironment of the failing heart.
A growing body of evidence suggests that regulatory T cells (Tregs), a subset of T lymphocytes with immunosuppressive properties, may participate in repair and remodeling of the infarcted myocardium. During the inflammatory phase of cardiac repair, Tregs infiltrate the infarcted myocardium, recruited through the activation of chemokine-dependent signals. 3 Infiltrating Tregs play an important role in repair of the infarcted heart and protect from cardiac rupture and adverse remodeling by driving activation of reparative macrophages 4 and by modulating fibroblast phenotypes. 5 The protective reparative functions of Tregs in the infarcted heart may involve systemic anti-inflammatory actions, local secretion of anti-inflammatory cytokines and growth factors, or contact-dependent effects. Although Tregs are key orchestrators of the reparative response following acute myocardial injury, their potential role in chronic ischemic heart failure has not been studied. Under the assumption that infarct Tregs maintain a stable anti-inflammatory phenotype, one would have expected that they may exert prolonged protective effects on the remodeling myocardium by attenuating the activation of macrophages and effector T cells. On that basis, it has been speculated that cell therapy with Tregs may be a promising approach for patients surviving acute myocardial infarction.
In the current issue of Circulation, Bansal and coworkers 6 report that, in contrast to their reparative role in myocardial infarction, Tregs in mice with chronic ischemic heart failure exhibit functional perturbations and acquire a proinflammatory phenotype, contributing to the progression of adverse remodeling. In a mouse model of nonreperfused myocardial infarction, chronic heart failure was associated with marked and prolonged expansion of Tregs in the heart, spleen, and circulating blood. During the chronic phase of cardiac remodeling, Tregs in failing hearts exhibited proinflammatory properties and impaired immunoregulatory capacity. Depletion of Tregs in mice with established postinfarction heart failure, using either a genetic approach based on a diphtheria toxin system, or treatment with an antibody to CD25, protected the heart from progressive dilation and even reversed adverse remodeling, decreasing systemic inflammation, reducing interstitial myocardial fibrosis, and attenuating capillary rarefaction.
The study challenges conventional views on the phenotypic stability of Tregs following tissue injury, demonstrating that, following myocardial infarction, Tregs undergo a phenotypic transition from a reparative phenotype to a dysfunctional proinflammatory cell type that contributes to the pathogenesis of heart failure. The findings also raise several intriguing questions regarding the emerging role of Tregs in myocardial injury, repair, and remodeling.
WHICH MOLECULAR SIGNALS MEDIATE EXPANSION OF DYSFUNCTIONAL TREGS IN CHRONIC HEART FAILURE?
Traditional teachings suggest that Tregs function predominantly as immunosuppressive and anti-inflammatory cells. In contrast to these established concepts, a growing body of experimental evidence in both experimental models and in human patients suggests that, under inflammatory conditions, Tregs can be reprogrammed into T-helper cells that secrete proinflammatory cytokines. 7 In many pathological conditions, the functional in vivo role of these dysregulated, proinflammatory Tregs remains debated. The current investigation provides robust evidence, through both genetic and pharmacological approaches, supporting the notion that perturbed Treg function may be an essential contributor to chronic myocardial injury.
The molecular basis for the heart failure-associated perturbations in Treg phenotype and function is unknown (Figure) . It should be emphasized that similar proinflammatory alterations have been reported in Tregs associated with a variety of inflammatory conditions, including psoriasis, inflammatory bowel disease, arthritis, and multiple sclerosis. 7 Thus, this common process of dysregulation may not be unique to heart failure, but may involve activation of inflammatory signaling cascades. Induction and prolonged secretion of proinflammatory cytokines are hallmarks of chronic heart failure; chronic cytokine stimulation may promote differentiation of Tregs into T helper 17 (Th17)-like cells with proinflammatory properties. 8 Although conversion of Tregs into other T-cell subsets has not been documented in the failing heart, several mechanisms may contribute to the acquisition of a proinflammatory phenotype in heart failure-associated Tregs. Activation of Toll-like receptor 2 signaling is also prominent in failing hearts and has been suggested to stimulate interleukin-17A expression in Tregs. 9 Activation of the renin-angiotensinaldosterone system or adrenergic stimulation promotes proinflammatory actions in both macrophages and lymphocytes. 10, 11 Whether neurohumoral stimulation of Tregs may be involved in acquisition of a dysfunctional proinflammatory phenotype remains unknown. Moreover, in the remodeling failing heart, Tregs are exposed to increased mechanical stress and are enmeshed within an interstitium enriched with a wide range of specialized extracellular matrix proteins 12 capable of modulating immune cell phenotype and function. Whether activation of mechanosensitive pathways or stimulation of matricellular actions may contribute to the perturbed phenotype of Tregs in failing hearts is unknown. Regardless of the initial activating stimulus, acquisition of a proinflammatory phenotype by heart failure Tregs may also involve perturbations of the nuclear factor-κB signaling cascade, an essential pathway for the maintenance of Treg function. It has been suggested that activation of noncanonical nuclear factor-κB signaling via accumulation of nuclear factor-κB-inducing kinase may promote Treg instability, inducing proinflammatory gene synthesis.
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WHICH TREG-MEDIATED SIGNALS EXACERBATE CHRONIC CARDIAC REMODELING?
Several cellular mechanisms may explain the adverse consequences of Treg perturbations on myocardial function. First, loss of immunosuppressive functions of Tregs may result in unrestrained activation of immune cells, leading to progressive cardiomyocyte death. Second, unopposed systemic and myocardial activation of effector T cells may accentuate proinflammatory signaling, promoting cytokine-driven myocardial dysfunction and activating fibrogenic cascades. Third, dysfunctional Tregs may promote a proinflammatory phenotype in macrophages, thus amplifying the consequences of perturbed Treg function on the inflammatory milieu. Fourth, as suggested by the current study, heart failure Tregs may exert contact-dependent angiostatic effects, leading to capillary rarefaction in the noninfarcted remodeling myocardium and accentuating ventricular dysfunction. Fifth, Tregs in failing hearts may acquire a matrix-degrading phenotype, leading to release of matrix fragments and disruption of prosurvival effects of the intact matrix on cardiomyocytes. Considering the relatively low myocardial density of Tregs in failing mouse hearts, a combination of direct actions of Tregs infiltrating the myocardium and effects on systemic inflammatory responses may account for the striking consequences of Treg-mediated actions in heart failure.
DOES PERTURBED TREG FUNCTION PLAY A ROLE IN THE PATHOGENESIS OF HUMAN HEART FAILURE?
Despite growing experimental evidence on the role of immune cells in the pathogenesis of heart failure in animal models, robust evidence on the phenotypic changes in inflammatory cell populations in human patients with heart failure is scarce. Defective immunosuppressive function of circulating Tregs has been reported in a population of patients with heart failure; similar patterns of dysfunction were noted in subgroups with ischemic or nonischemic etiology.
14 Whether Treg dysfunction in human patients with heart failure is associated with inflammatory conversion remains unknown. A, Tregs are recruited in the infarcted myocardium, exhibiting 2 waves of infiltration. The marked expansion of cardiac Tregs during the inflammatory and proliferative phase of infarct healing (3-7 days after coronary occlusion) is followed by a late, less striking increase in Treg density during the phase of chronic remodeling (8 weeks after infarction). B, Early recruitment of Tregs in the infarct is mediated through chemokine-dependent pathways. 3 Reparative Tregs play an important role in suppression of postinfarction inflammation and in repair of the infarcted heart by dowmodulating proinflammatory activity in macrophages (Ma) and effector T cells (Teff) and by activating fibroblasts. 4, 5 During the chronic phase of cardiac remodeling, Tregs have functional perturbations, exhibiting defective immunosuppressive and anti-inflammatory activity, producing proinflammatory cytokines, and exerting fibrogenic and angiostatic actions. The molecular signals promoting expansion of dysfunctional Tregs are poorly understood, but may involve chronic stimulation with proinflammatory cytokines, neurohumoral activation, and stimulation of Toll-like receptor signaling. The study by Bansal and coworkers 6 demonstrates that dysfunctional Tregs play an important role in progression of adverse remodeling in chronic ischemic cardiomyopathy. CC indicates CC chemokine; CXC, CXC chemokine; EC, endothelial cell; MV, microvessel; IL, interleukin; and TNF, tumor necrosis factor.
